-
Something wrong with this record ?
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Héctor Bueno, Brenda Moura, Patrizio Lancellotti, Johann Bauersachs
Language English Country Czech Republic
- MeSH
- Angiotensin Receptor Antagonists therapeutic use MeSH
- Biomarkers MeSH
- Cardiomyopathies diagnosis therapy MeSH
- Humans MeSH
- Neprilysin therapeutic use MeSH
- Heart Failure * diagnosis therapy MeSH
- Tetrazoles therapeutic use MeSH
- Check Tag
- Humans MeSH
During year 2020, we learned new options to better stratify patients with heart failure and preserved left ventricular ejection fraction (HFpEF) (A), the clinical benefit of three new drugs to improve prognosis of patient with heart failure and reduced left ventricular ejection fraction (HFrEF): empagliflozin, vericiguat and omecamtiv mecarbil (B), the potential benefit of a broader utilization of recommended drugs for HFrEF in patients with left ventricular ejection fraction higher than 40% (C), and the potential added clinical benefit of a comprehensive use of recommended drugs for HFrEF (D) in a year marked by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (central cartoon). Reprinted or adapted from: (A) Selvaraj et al.,23 (B) Packer et al.,115 Armstrong et al.,126 and Teerlink et al.,132 (C) Böhm et al.,100 (D) Vaduganathan et al.139 (Graphical Abstract - see in original.)
Cardiology Department Military Hospital Av da Boavista S N 4050 115 Porto Portugal
Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares Madrid Spain
Facultad de Medicina Universidad Complutense de Madrid Plaza de Ramón y Cajal s n 28040 Madrid Spain
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22002190
- 003
- CZ-PrNML
- 005
- 20220203122957.0
- 007
- ta
- 008
- 220110s2021 xr d f 000 0|eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Bueno, Héctor $u Multidisciplinary Translational Cardiovascular Research Group. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro, 3, Madrid 28029, Spain $u Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital, 12 de Octubre (imas12), Madrid, Spain $u Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Madrid, Spain $u Facultad de Medicina, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain
- 245 14
- $a The year in cardiovascular medicine 2020: heart failure and cardiomyopathies / $c Héctor Bueno, Brenda Moura, Patrizio Lancellotti, Johann Bauersachs
- 520 9_
- $a During year 2020, we learned new options to better stratify patients with heart failure and preserved left ventricular ejection fraction (HFpEF) (A), the clinical benefit of three new drugs to improve prognosis of patient with heart failure and reduced left ventricular ejection fraction (HFrEF): empagliflozin, vericiguat and omecamtiv mecarbil (B), the potential benefit of a broader utilization of recommended drugs for HFrEF in patients with left ventricular ejection fraction higher than 40% (C), and the potential added clinical benefit of a comprehensive use of recommended drugs for HFrEF (D) in a year marked by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (central cartoon). Reprinted or adapted from: (A) Selvaraj et al.,23 (B) Packer et al.,115 Armstrong et al.,126 and Teerlink et al.,132 (C) Böhm et al.,100 (D) Vaduganathan et al.139 (Graphical Abstract - see in original.)
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 17
- $a srdeční selhání $x diagnóza $x terapie $7 D006333 $2 czmesh
- 650 _7
- $a kardiomyopatie $x diagnóza $x terapie $7 D009202 $2 czmesh
- 650 _7
- $a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911 $2 czmesh
- 650 _7
- $a biologické markery $7 D015415 $2 czmesh
- 650 _7
- $a neprilysin $x terapeutické užití $7 D015260 $2 czmesh
- 650 _7
- $a tetrazoly $x terapeutické užití $7 D013777 $2 czmesh
- 700 1_
- $a Moura, Brenda $u Cardiology Department, Military Hospital, Av. da Boavista S/N , 4050-115 Porto, Portugal $u CINTESIS—Center for Health Technology and Services Research , R. Dr. Plácido da Costa, 4200-450 Porto, Portugal
- 700 1_
- $a Lancellotti, Patrizio $u Department of Cardiology, CHU SartTilman, University of Liège Hospital, GIGA Cardiovascular Sciences, Avenue de L'Hôpital 1, 4000 Liège, Belgium $u Cardiology Departments, Gruppo Villa Maria Care and Research, Maria Cecilia Hospital , Cotignola Bari, Italy and Via Corriera, 1, 48033 Cotignola RA, Italy and Anthea Hospital, Via Camillo Rosalba, 35/37, 70124 Bari BA, Italy
- 700 1_
- $a Bauersachs, Johann $u Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- 773 0_
- $t Cor et Vasa $x 0010-8650 $g Roč. 63, Suppl. 1 (2021), s. 38-51 $w MED00010972
- 856 41
- $u https://e-coretvasa.cz/en/artkey/cor-202188-0005_the-year-in-cardiovascular-medicine-2020-heart-failure-and-cardiomyopathies.php $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 2980 $c 438 $y p $z 0
- 990 __
- $a 20220110 $b ABA008
- 991 __
- $a 20220203122950 $b ABA008
- 999 __
- $a ok $b bmc $g 1750670 $s 1153338
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 63 $c Suppl. 1 $d 38-51 $e 20210701 $i 0010-8650 $m Cor et Vasa (Brno) $x MED00010972
- LZP __
- $c NLK109 $d 20220203 $b NLK111 $a Actavia-MED00010972-20220110
